Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 40HER2 Positive Metastatic Breast Cancer 4Breast Diseases 4Brain Neoplasms 4Carcinoma, Non-Small-Cell Lung 3Stomach Neoplasms 2HER2-positive Breast Cancer 2Colorectal Neoplasms 2Advanced Breast Cancer 2Triple Negative Breast Neoplasms 1Solid Tumor 1Salivary Gland Neoplasms 1Pathologic Complete Response 1Neoplasm Metastasis 1Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer 1HER2-positive Metastatic Breast Cancer 1HER2+ Early or Locally Advanced Breast Cancer 1HER2+ Breast Cancer 1HER2 Positive Gastric Cancer 1HER2 Positive Breast Cancer 1HER-2 Positive Colorectal Cancer 1Estrogen Receptor-positive Breast Cancer 1Digestive System Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

pyrotinib 1Trastuzumab 1Drug Therapy 1Docetaxel 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × HER2-positive Metastatic Breast Cancer × pyrotinib × Clear all
NCT05042791 2024-02-09

A Study of Pyrotinib Plus Capecitabine Combined With SRT in HER2+ MBC With Brain Metastases

Jiangxi Provincial Cancer Hospital

Phase 2 Unknown
362 enrolled
Breast

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡